ArticleDiscover oncology2025
Anticancer role of Gramicidin A in myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMyeloid and lymphoid progenitor cells can develop leukemia. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two types of myeloid leukemia, depending on how the disease progresses. Acute promyelocytic leukemia (APL) a subtype of AML and CML were the main subjects of this investigation. Despite the encouraging results of FDA-approved therapies, there is still relapse and no cure. Although it has recently been demonstrated that the well-known antibiotic gramicidin A (GA) inhibits the growth of tumor cells, the mechanism of action have not been investigated in leukemia.
methodsThis study used pharmacological and biochemical approaches to investigate anticancer potential and mechanism of action of GA in APL and CML.
resultsWe report that, irrespective of apoptosis induction, GA inhibits the proliferative potential of APL and CML cell lines (p < 0.05 and p < 0.0001). GA down regulate expression of AXL-RTK and EYA3 genes which are regulators of Wnt/β-catenin pathway. Furthermore we showed that Wnt/β-catenin target genes including c-Myc and Axin2 were down regulated which were also linked to the additive anticancer effect of GA in combination with Imatinib for CML and ATRA for APL (p < 0.0001). Moreover, hemolysis of red blood cell (RBCs) was not induced by any inhibitory concentration of GA.
conclusionAccording to our findings, GA significantly reduces the leukemogenic potential of APL and CML without causing any hemolysis in RBCs, indicating its safety profile with respect to red blood cell integrity, and may eventually be a viable substitute/candidate for therapeutic intervention in APL and CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.